Tocilizumab Injection (Actemra)

Elliott, William T.; Chan, James
February 2010
Internal Medicine Alert;2/28/2010, Vol. 32 Issue 4, p30
The article offers pharmacological updates on Tocilizumab injection (Actemra) for treating rheumatoid arthritis (RA).


Related Articles

  • The pharmacogenetics of methotrexate. S. L. Hider; I. N. Bruce; W. Thomson // Rheumatology;Sep2007, Vol. 46 Issue 10, p1520 

    Methotrexate (MTX) is a cornerstone of therapy for rheumatoid arthritis. However, it is not universally effective and up to one-third of patients fail to respond to treatment, either because of inefficacy or adverse events, although at present it is not possible to predict therapy response...

  • NEWSLINE.  // MPR - Pharmacist's Edition;Winter2012/2013, Vol. 6 Issue 4, pA-8 

    The article focuses on news briefs related to the drug approvals. Approval for the treatment of moderately-to-severely active rheumatoid arthritis (RA) has been given to the drug Xeljanz tablets in patients who have had an inadequate response or intolerance to methotrexate. Clinical remission is...

  • Clinical Pharmacology and Therapeutic Potential of Monoclonal Antibody Treatment in Rheumatoid Arthritis. Choy, E.H.S. // Drugs & Aging;1998, Vol. 12 Issue 2, p139 

    Many monoclonal antibodies (mAb) have been tested in rheumatoid arthritis (RA). Murine antibodies were antigenic and caused human antimouse responses in the recipients. As a result, re-treatments were less effective and were associated with an increased risk of anaphylaxis. Advances in...

  • Pharmacology and Toxicology of Leflunomide. LODHI, RAM LAL; SARAF, SHUBHINI A.; KAITHWAS, GAURAV; SAHA, SUDIPTA // Iranian Journal of Pharmacology & Therapeutics;Jun2012, Vol. 11 Issue 1, p26 

    Leflunomide (LEF), used for rheumatoid arthritis, inhibits dihydro-orotate dehydrogenase (DHODH) and tyrosine kinase (TK) enzymes and has anti-inflammatory, lymphocyte proliferation regulatory, immunosuppression and chondroprotective effects. The most common adverse effects are gastrointestinal...

  • Abatacept. Cada, Dennis J.; Levien, Terri; Baker, Danial E. // Hospital Pharmacy;Aug2006, Vol. 41 Issue 8, p772 

    The article provides information on abatacept, a biologic agents used in reducing the signs and symptoms of rheumatoid arthritis. Indications for other similar biologic agents used in the treatment of rheumatoid arthritis, such as adalimumab are summarized. The pharmacokinetics and efficacy of...

  • Non-drug care for RA—is the era of evidence-based practice approaching? Vlieland, T. P. M. Vliet // Rheumatology;Sep2007, Vol. 46 Issue 9, p1397 

    Non-pharmacological treatment modalities are often recommended, prescribed and used in addition to drug treatment in patients with rheumatoid arthritis (RA). This article provides a review of the literature on their effectiveness.

  • Prediction of Creatinine Clearance from Serum Creatinine in Patients with Rheumatoid Arthritis: Comparison of Six Formulae and One Nomogram. Anders, H-J.; Rihl, M.; Loch, O.; Schattenkirchner, M. // Clinical Rheumatology;Jan2000, Vol. 19 Issue 1, p26 

    : The estimation of glomerular filtration rate is important for the medical treatment of patients with rheumatoid arthritis (RA). However, the determination of endogenous creatinine clearance (Clcr) from a 24-h urine collection is an unreliable and time-consuming procedure. We therefore tested...

  • Defining Immunological Impact and Therapeutic Benefit of Mild Heating in a Murine Model of Arthritis. Lee, Chen-Ting; Kokolus, Kathleen M.; Leigh, Nicholas D.; Capitano, Maegan; Hylander, Bonnie L.; Repasky, Elizabeth A. // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    Traditional treatments, including a variety of thermal therapies have been known since ancient times to provide relief from rheumatoid arthritis (RA) symptoms. However, a general absence of information on how heating affects molecular or immunological targets relevant to RA has limited heat...

  • Golimumab gets the green light for QOL in RA.  // PharmacoEconomics & Outcomes News;12/13/2008, Issue 568, p8 

    The article focuses on a study presented at the 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) which showed that the use of golimumab to treat rheumatoid arthritis (RA) resulted in significant improvements in self-reported...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics